June 10, 2024

Roche Announces Phase II Open-Label SHIELD DMD Study to Assess Effect of Satralizumab on Bone Health in Duchenne

Today Roche announced plans for the SHIELD DMD study, a phase II open-label study to investigate the use of satralizumab in ambulatory and non-ambulatory individuals with Duchenne. Satralizumab is a monoclonal antibody that inhibits interleukin-6…

Learn More

January 23, 2020

End Duchenne Tour Connect Group Session: Houston, TX

PPMD’s End Duchenne Tour made a stop in Houston, TX on Saturday, January 18. We were joined by over 40 people, including PPMD’s Connect Coordinators for South Texas, several PPMD families, and some of the…

Learn More

November 6, 2019

Roche/Genentech Announces Decision to Discontinue Development of RG6206 (RO7239361)

We are disappointed to learn that Roche/Genentech is discontinuing development of their investigational anti-myostatin adnectin RG6206 (RO7239361) for the treatment of Duchenne. According to the company, this decision was based on results from a pre-planned…

Learn More

July 18, 2019

Roche/Genentech Announces Completed Recruitment for SPITFIRE Study

Roche/Genentech has provided an update to the community announcing that enrollment in the SPITFIRE pivotal study has been officially completed globally at 48 sites across the US, Canada, Argentina, Europe, Australia and Japan. Read Roche/Genentech’s letter…

Learn More

February 27, 2019

Roche/Genentech General Program Update Letter to the Duchenne Community

As Roche/Genentech continues to advance its Phase 2/3 clinical development program for RG6206, an adnectin fusion protein designed to inhibit myostatin and stimulate muscle growth in ambulatory people with Duchenne, the company has provided an…

Learn More

February 19, 2019

End Duchenne Tour Recap: Las Vegas, NV

PPMD was thrilled to head to Las Vegas, NV for our first End Duchenne Tour stop of 2019 on February 2. More than 45 people came together to learn about the latest information and resources for Duchenne…

Learn More

December 17, 2018

End Duchenne Tour Recap: Cincinnati, OH

PPMD headed to Cincinnati, OH for our End Duchenne Tour stop on November 17, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families. PPMD…

Learn More

November 29, 2018

End Duchenne Tour Recap: Palo Alto, CA

PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families….

Learn More

October 15, 2018

WATCH: Is Myostatin Still a Potential Therapeutic Target? – Webinar Recording

Myostatin is a negative regulator of muscle growth – a protein that stops muscle building and doesn’t let them get too big, as part of the natural regeneration process. In other words, if we can…

Learn More

September 13, 2018

Genentech/Roche RG6206 Community Letter

  Today, Roche provided the community on their clinical development program of RG6206, an investigational anti-myostatin adnectin that is designed to block the activity of myostatin. Roche also answers questions they have received in light…

Learn More